Invest in Taysha Gene Therapies, Inc. on Stash
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system.
Ticker: TSHA
Taysha Gene Therapies, Inc.
$6.57
-2.38%
$
TSHA Performance Breakdown
Share Price
$6.57
Today's change
1.23%
Year to date change (YTD)
25.14%
Dividend yield
0.0
Last dividend paid
N/A
Last dividend pay date
N/A
About TSHA
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.
Taysha Gene Therapies, Inc. Stock Ticker
TSHA
For more information
Invest in Taysha Gene Therapies, Inc. on Stash
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system.
Certain companies are volatile
Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.
Taysha Gene Therapies, Inc. stock news
Why invest with Stash?
Fractional shares
Thousands of stocks and ETFs. No investing minimums.
Unlimited trades
Plus no add-on trading commission fees.†
Diversification analysis
Custom investment recommendations can help you diversify.
Automatic investing
Dividend reinvestment,8 recurring investments, and more.
The Stock-Back® Card
We’ll give you matching stock in companies you shop at.1
Learn how to invest
Get professional advice and education at every step.
How to buy Taysha Gene Therapies, Inc. stock on Stash
Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.
Stash offers one subscription plan: The Stash Plan.
Once your market order of Taysha Gene Therapies, Inc. stock is complete, you'll officially be a shareholder of Taysha Gene Therapies, Inc.!
Invest in Taysha Gene Therapies, Inc. on Stash
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system.
More Health Care stocks
First Tracks Biotherapeutics, Inc.
53.01%
Semnur Pharmaceuticals, Inc.
18.46%
10x Genomics Inc Class A
12.86%
CONMED Corp
12.03%
Neurogene, Inc.
11.96%
Hemab Therapeutics Holdings, Inc.
9.81%
Damora Therapeutics, Inc.
9.66%
Qiagen NV
9.53%
Butterfly Network Inc.
8.79%
Treace Medical Concepts Inc
8.64%
Tempus AI, Inc. Class A
7.39%



